The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in
AD treatment.
We learned at CTAD 2018 of the importance of non-pharmaceutical trials
and that anti-amyloid treatment for AD should begin early on in the
disease process. Furthermore we also learned more of another pathway
with Tau Biomarkers, and their implications for AD along with
combination therapeutics and phase 3 clinical trials results. Again in
2019 Clinical teams will present their population studies on subjects in
the early stage of the disease or even at the asymptomatic stage.
